GYRE Valuation

Gyre Therapeutics Inc

Add to Watchlist

Advanced Chart

6.650

-0.4(-5.674%)1D

Overview
Forecast
Valuation
Earnings

GYRE Relative Valuation

GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GYRE is overvalued; if below, it's undervalued.

Historical Valuation

Gyre Therapeutics Inc (GYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 6.09. The fair price of Gyre Therapeutics Inc (GYRE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：6.85

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Gyre Therapeutics Inc. (GYRE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.00

EV/EBIT

Gyre Therapeutics Inc. (GYRE) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 1.65. The thresholds are as follows: Strongly Undervalued below -9.14, Undervalued between -9.14 and -3.74, Fairly Valued between 7.05 and -3.74, Overvalued between 7.05 and 12.45, and Strongly Overvalued above 12.45. The current Forward EV/EBIT of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

Gyre Therapeutics Inc. (GYRE) has a current PS of 0.00. The 5-year average PS is 0.60. The thresholds are as follows: Strongly Undervalued below -3.29, Undervalued between -3.29 and -1.35, Fairly Valued between 2.54 and -1.35, Overvalued between 2.54 and 4.48, and Strongly Overvalued above 4.48. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

12.73

P/OCF

Gyre Therapeutics Inc. (GYRE) has a current P/OCF of 12.73. The 5-year average P/OCF is 4.17. The thresholds are as follows: Strongly Undervalued below -12.27, Undervalued between -12.27 and -4.05, Fairly Valued between 12.40 and -4.05, Overvalued between 12.40 and 20.62, and Strongly Overvalued above 20.62. The current Forward P/OCF of 12.73 falls within the Overvalued range.

0.00

P/FCF

Gyre Therapeutics Inc. (GYRE) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 9.35. Compared to its 3-year average P/B ratio of -8.47 , the current P/B ratio is approximately -210.44% higher. Relative to its 5-year average P/B ratio of -8.47, the current P/B ratio is about -210.44% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately -1.34%. Compared to its 3-year average FCF yield of -0.08%, the current FCF yield is approximately 1664.96% lower. Relative to its 5-year average FCF yield of -0.08% , the current FCF yield is about 1664.96% lower.

9.35

P/B

Median3y

-8.47

Median5y

-8.47

-1.34

FCF Yield

Median3y

-0.08

Median5y

-0.08

Competitors Valuation Multiple

The average P/S ratio for GYRE's competitors is 880.20, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -18.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GYRE.O

Gyre Therapeutics Inc

Phathom Pharmaceuticals Inc

ATAI Life Sciences NV

5217.69

884.64M

EYPT.O

EyePoint Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

19.79

659.89M

Performance Decomposition

Market capitalization of GYRE decreased by 48.80% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 283.54 to 350.77.

The secondary factor is the Revenue Growth, contributed -18.82%to the performance.

Overall, the performance of GYRE in the past 1 year is driven by P/E Change. Which is more unsustainable.

-18.82%

27.17M → 22.06M

Revenue Growth

-53.69%

36.56 → 16.93

Margin Expansion

23.71%

283.54 → 350.77

P/E Change

-48.80%